At a glance
- Originator Novartis
- Class Antifungals
- Mechanism of Action Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 20 Nov 1995 Discontinued-Preclinical for Mycoses in Switzerland (Unknown route)